期刊
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
卷 19, 期 6, 页码 471-476出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCO.0000000000000314
关键词
dietary polyphenols; gut microbiota; interindividual variability; metabotype; microbial metabolites
资金
- BACCHUS [FP7-KBBE-2012-6-single stage]
- BACCHUS (European Commission) [312090]
- MINECO, Spain [CICYT-AGL2011-22447, AGL2015-64124-R]
- CSIC, Spain [201370E068]
- Fundacion Seneca Region de Murcia [19900/GERM/15]
- COST Action [FA1403 POSITIVe]
Purpose of reviewDietary (poly)phenolic compounds have received attention over the last 20 years as antioxidants with preventive properties against chronic diseases. However, the evidence of these effects in clinical trials is weak, mainly because of a considerable interindividual variability. Polyphenols bioavailability is low, and gut microbiota metabolize them into simpler metabolites. As gut microbiota vary among individuals, such interindividual variability should be considered as a moderating factor in clinical trials. In this review, we show evidence of interactions with gut microbiota that help understanding polyphenols' health effects.Recent findingsRecent studies indicate that dietary polyphenols are relevant in the modulation of gut microbiota and that these microorganisms convert polyphenols into active and bioavailable metabolites; hence, variations in gut microbiota can affect polyphenol activity.SummaryThe results show that study participants' stratification by their polyphenol-metabolizing phenotypes would be necessary for clinical trials as specific metabotypes produce the bioactive metabolites responsible for the health effects. Metabotypes can also reflect the gut microbiota composition and metabolic status, and could be biomarkers of the potential polyphenol health effects mediated through gut microbiota.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据